Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
IIPR Innovative Industrial Properties Inc
NVCN Neovasc Inc
CDE Coeur Mining Inc
BRID Bridgford Foods Corp
SOR Source Capital Inc
RCLFW Rosecliff Acquisition Equity I Warrants Exp 11 Feb 2026 *W EXP 02/11/2026
FAST Fastenal Co
UKOMW Ucommune International Equity Warrant Exp 17th Nov 2025 *W EXP 11/17/2025
KMI Kinder Morgan Inc
Go


Based in Canada
Company profile

Cybin Inc. is a Canada-based biopharmaceutical company, working with a network of partners and scientists to create therapeutics for patients to address a multitude of mental health issues. The Company operates in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. The Company’s products in pipeline include EMBARK, Kernel Flow, CYB003 (Deuterated Psilocybin Analog), CYB004 (Deuterated Dimethyltryptamine), and CYB005 (Phenethylamine Derivative). EMBARK is a Psilocybin for mental distress in frontline healthcare workers. Its subsidiaries include Cybin Corp., Natures Journey Inc., Serenity Life Sciences Inc., Cybin US Holdings Inc., Adelia Therapeutics Inc. and Cybin IRL Limited.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$0.5782
Day's Change
-0.0008 (-0.14%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.5899
Day's Low
0.56
Volume
(Light)
Volume:
293,032

10-day average volume:
488,286
293,032

Display:

Providers:

UpdateCancel
6 providers
June 27, 2022
Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary...(BusinessWire)

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced that it has received a "may proceed letter" and Investigational New Drug...(BusinessWire)

June 22, 2022
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today reported audited financial results for its fiscal year ended March 31, 2022 and...(BusinessWire)

June 16, 2022
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate...(BusinessWire)

June 15, 2022
World's Richest Man Says Psychedelics Could Make a Real Difference in Mental Health

FN Media Group Presents Microsmallcap.com Market Commentary Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of mental health conditions. The Tesla CEO said in a tweet last month that...(PR Newswire)

June 09, 2022
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced that it has received Institutional Review Board ("IRB") approval to begin the...(BusinessWire)

June 07, 2022
Cybin Acquires DMT Clinical Study from Entheon Biomedical

-- Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical path forward -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing...(BusinessWire)

June 03, 2022
Cybin Announces Additional Adelia Milestone Achievements

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary...(BusinessWire)

Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced the team of 28 esteemed faculty and advisors who will lead the Company's...(BusinessWire)

June 02, 2022
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", is pleased to announce the publication of a peer-reviewed article introducing EMBARK, a...(BusinessWire)

Cybin to Host Key Opinion Leader Webinar on June 9, 2022

--- Deep dive into the psychedelics landscape and overview of current and emerging psychedelic-based treatments - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics...(BusinessWire)

May 31, 2022
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", is pleased to announce the submission of an Investigational New Drug ("IND") application to the...(BusinessWire)

May 17, 2022
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to announce that it will participate in the morning trading bell ceremony on May 18...(BusinessWire)

May 11, 2022
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate...(BusinessWire)

May 09, 2022
Cybin and Kernel Announce Results from Kernel Flow(R) Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

--- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing "Psychedelics...(BusinessWire)

Cybin and Kernel Announce Results from Kernel Flow(R) Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

--- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing "Psychedelics...(BusinessWire)

May 05, 2022
Cybin Announces CYB003 Poster to be Presented at the 'From Research to Reality' Global Summit on Psychedelic-Assisted Therapies and Medicine

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced that an abstract highlighting preclinical data for its deuterated psilocybin...(BusinessWire)

April 22, 2022
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at...(BusinessWire)

April 21, 2022
Roth Capital Reveals Top Psychedelic Picks in New Industry Report

FN Media Group Presents Microsmallcap.com Market Commentary Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report from Roth Capital is no exception. On April 19, Roth Capital analyst Elemer Piros...(PR Newswire)

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced that it has partnered with Clinilabs Drug Development Corporation...(BusinessWire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.